The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Value Of The Artificial Intelligence (AI) In Drug Discovery Market Progress Between 2026 And 2030?
The artificial intelligence (AI) in drug discovery market has seen substantial expansion in recent years. Its value is projected to grow from $2.33 billion in 2025 to $2.93 billion in 2026, at a compound annual growth rate (CAGR) of 25.9%. Historically, this growth has been driven by increasing pharmaceutical R&D spending, the growing complexity of drug discovery pipelines, rising availability of biological and chemical datasets, early adoption of machine learning in bioinformatics, and increasing collaboration between pharma and tech firms.
The artificial intelligence (AI) in drug discovery market size is anticipated to experience significant growth in the coming years. It is projected to expand to $7.42 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 26.2%. This growth during the forecast period is driven by factors such as the increasing adoption of generative AI models, a rising demand for precision therapeutics, the expansion of AI-enabled clinical trial design, growing investments in cloud-based discovery platforms, and regulatory acceptance of AI-assisted drug development. Noteworthy trends in the forecast period include the increasing use of AI-driven target identification, a rising adoption of deep learning for molecule screening, the growing integration of virtual drug screening platforms, the expansion of AI-based lead optimization tools, and an enhanced focus on reducing drug development timelines.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Major Drivers Are Influencing The Expansion Of The Artificial Intelligence (AI) In Drug Discovery Market?
The increasing need for personalized medicine is projected to drive the expansion of artificial intelligence (AI) within the drug discovery market. Personalized medicine involves a focused strategy for preventing, diagnosing, and treating diseases, utilizing an individual’s genetic, proteomic, or biological information to inform medical choices. The increasing uptake of personalized medicine is fueled by the growing requirement for exact, patient-tailored treatments that enhance therapeutic efficacy and minimize negative reactions. AI facilitates this transition by speeding up the discovery of molecular targets, refining potential drugs, and improving clinical judgments across the entire development process. For example, in February 2024, the Personalized Medicine Coalition, a US-based advocacy and research entity, reported that the U.S. FDA cleared 26 novel personalized therapies in 2023, comprising 20 new molecular entities and 6 therapies based on genes or cells. Consequently, the escalating demand for personalized medicine is propelling the advancement of artificial intelligence (AI) in the drug discovery market.
How Are Different Segments Classified In The Artificial Intelligence (AI) In Drug Discovery Market Segment Analysis?
The artificial intelligence (AI) in drug discovery market covered in this report is segmented –
1) By Technology: Context-Aware Processing, Natural Language Processing, Deep Learning
2) By Drug Type: Small Molecules, Large Molecules
3) By Therapeutic Type: Metabolic Disease, Cardiovascular Disease, Oncology, Neurodegenerative Diseases, Anti-Infective Diseases, Respiratory Diseases, Other Therapeutics
4) By End User: Pharmaceutical Companies, Biopharmaceutical Companies, Academic And Research Institutes, Other End-Users
Subsegments:
1) By Context-Aware Processing: Contextual Data Integration, Predictive Modeling, Adaptive Learning Systems
2) By Natural Language Processing (NLP): Text Mining And Analysis, Drug Interaction Extraction, Clinical Trial Data Analysis
3) By Deep Learning: Neural Networks, Convolutional Neural Networks (CNNs), Recurrent Neural Networks (RNNs), Reinforcement Learning Applications
Which Trends Are Shaping The Artificial Intelligence (AI) In Drug Discovery Market?
Leading corporations are allocating capital to firms involved in artificial intelligence (AI) within the drug discovery sector, aiming to pinpoint and develop novel treatments and subsequently provide these methodologies to other pharmaceutical manufacturers. Such strategic financial backing is crucial for supporting the research and development of novel pharmaceuticals, an endeavor known for being both expensive and protracted. This capital infusion enables companies to accelerate their drug discovery initiatives and introduce innovative therapies to the market. An example of this trend is Nvidia, a software firm based in the US, which in July 2023 committed $50 million to Recursion Pharmaceuticals, a US-based biotechnology company that leverages artificial intelligence (AI) for drug discovery purposes. This particular investment is intended to empower Recursion in expediting the creation of its foundational AI models for biological and chemical applications, utilizing Nvidia’s suite of cloud services.
Who Are The Companies Driving Activity In The Artificial Intelligence (AI) In Drug Discovery Market?
Major companies operating in the artificial intelligence (AI) in drug discovery market are Exscientia, Insilico Medicine, Owkin Inc., XtalPi Inc., Standigm Inc., Innoplexus AG, Atomwise, Inc., BenevolentAI, Deep Genomics Inc., NuMedii, Inc., Verge Genomics, Inc., Berg LLC, Cyclica Inc., Iktos, Quris, Adagene Inc., Gero Pte. Ltd., IBM Corporation, Microsoft Corporation, NVIDIA Corporation, Alphabet Inc., DeepMind Technologies Limited, IQVIA Holdings Inc., GNS Healthcare, Inc., GE HealthCare Technologies Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., AbbVie Inc., AstraZeneca PLC, Amgen Inc., GlaxoSmithKline plc, Johnson & Johnson, Takeda Pharmaceutical Company Limited, Ipsen S.A., Galderma S.A.
Get The Full Artificial Intelligence (AI) In Drug Discovery Market Report:
Which Region Accounts For The Largest Portion Of The Artificial Intelligence (AI) In Drug Discovery Market?
North America was the largest region in the artificial intelligence (AI) in drug discovery market in 2025. Western Europe was the second largest region in the global artificial intelligence (AI) in drug discovery market share. The regions covered in the artificial intelligence (AI) in drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Artificial Intelligence (AI) In Drug Discovery Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Artificial Intelligence (AI) In Drug Discovery Market 2026, By The Business Research Company
Artificial Intelligence Ai In Predictive Toxicology Market Report 2026
Generative Artificial Intelligence Ai In Drug Discovery Market Report 2026
Artificial Intelligence Ai In Biopharmaceuticals Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model